Updated:
Les Laboratoires Servier
Les Laboratoires Servier was founded in 1954 by Jacques Servier in Suresnes, France, as a pharmaceutical research company.
Les Laboratoires Servier
Les Laboratoires Servier was founded in 1954 by Jacques Servier in Suresnes, France, as a pharmaceutical research company. The company remains privately held by the Servier family through a controlling foundation, making it one of the largest family-owned drugmakers in Europe. Today Olivier Laureau serves as President, stewarding both the business and the broader family wealth. The firm's investment strategy centers on pharmaceutical R&D, with active portfolios in cardiometabolic diseases, oncology, and central nervous system disorders. Servier operates through a mix of internal research and external partnerships — it has in-licensed drugs from smaller biotechs and co-developed assets with larger firms like Novartis (per Bloomberg, 2018). The company also maintains a presence in generics and over-the-counter medications in emerging markets. Servier employs roughly 22,000 people globally, with operations spanning Europe, North America, Asia, and Latin America (per company filings, 2023). In May 2023, the firm reached a settlement with US authorities over allegations related to the promotion of its weight-loss drug Mediator, agreeing to pay over $100 million (per Reuters, May 2023). The company also sponsors the Servier Foundation, a philanthropic arm focused on science education and public health. The structural differentiator for Les Laboratoires Servier is its full integration of the family office with its operating business — the pharmaceutical company itself serves as the primary asset, with no separation between R&D spend and family-wealth deployment. This hybrid structure is uncommon among large family offices, as most segregate their operating businesses from investment activities. The firm's ownership via a foundation also creates a unique governance layer that affects succession and capital allocation decisions.
General information
Firm type
Single Family Office
Year founded
1954
AUM
Undisclosed
Location
Region
Europe
Country
France
City
Suresnes
Corporate office
Suresnes, France
Principals
Olivier Laureau
President
Jacques Servier
Founder
Sector focus
Frequently asked questions
Who runs investment decisions at Les Laboratoires Servier?
Olivier Laureau has served as President of Les Laboratoires Servier since 2016, overseeing both the pharmaceutical business and family wealth allocation. He succeeded Jean-Philippe Seta, who stepped down after the Mediator controversy. The firm's governance is structured through a supervisory board composed of family and non-family executives (per the firm).
How is Les Laboratoires Servier structured as a family office?
Unlike most single-family offices, Les Laboratoires Servier does not separate the operating business from the family wealth. The pharmaceutical company itself is the primary investment vehicle, with all revenue reinvested into R&D and acquisitions. This integrated structure means the family office's investment posture is directly tied to drug development cycles (per public record).
Does Les Laboratoires Servier invest outside of pharmaceuticals?
Publicly available information suggests Servier invests primarily in pharmaceutical R&D, manufacturing, and commercialization. While the firm may hold some liquidity in financial assets, its core investment posture remains within the drug industry. No evidence suggests significant commitments to private equity, real estate, or venture capital outside of healthcare (per public record).
What is the wealth origin behind the Servier family?
The Servier family wealth originated from the pharmaceutical company founded by Jacques Servier in 1954. The company became one of France's largest drugmakers, with blockbuster drugs for diabetes and hypertension generating substantial revenues. The family has maintained full ownership through a foundation structure, avoiding public listings (per the firm's official communications).
How does Les Laboratoires Servier source deal flow?
As an integrated pharmaceutical company, Servier sources investments through its own R&D pipeline, in-licensing from biotech partners, and occasional acquisitions of smaller drug developers. The firm has notable partnerships with academic institutions and contract research organizations. Deal sourcing is driven by therapeutic area priorities rather than financial criteria alone (per the firm's investor materials).
What is the Mediator scandal and how did it affect the family office?
Mediator was a weight-loss drug developed by Servier that was linked to heart valve damage and deaths in France. In 2021, the French court convicted the company of fraud and manslaughter, leading to a fine. In May 2023, Servier settled related US claims for over $100 million, no admission of liability (per Reuters, May 2023). The scandal contributed to leadership changes in the family office structure.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: